Epitalon vs Epithalon: Names, Telomere Research and Limits
Published
Bookmark this page
Save this article in your browser so you can find it again:
- Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
- iPhone or iPad: In Safari, tap Share, then Add Bookmark.
- Android: In Chrome, open the menu and tap the star.
Other browsers may use a different menu.
Epitalon and Epithalon are alternative names used for the same reference tetrapeptide, Ala-Glu-Asp-Gly, also abbreviated AEDG. The National Library of Medicine lists both spellings in one controlled-vocabulary record. A spelling difference alone is therefore not evidence of a different compound. NLM identity record
The more important questions concern the specified chemical form, the material actually used in a study and what that experiment measured. Telomere findings in cultured human cells are not the same as a trial showing that people live longer.
Publisher disclosure: Bio Research LLC operates Bio Peptides Labs and sells Epithalon-labeled research materials. This is commercially interested, AI-assisted editorial content, not an independent scientific review. This focused guide uses the original-study records, selected publisher text and official sources linked below. It is not a systematic review or independent assessment of raw data. Sources checked November 11, 2026.

Epitalon vs Epithalon: check more than the spelling
An identity comparison should preserve sequence, terminal groups and chemical form. FDA's July 2026 compounding presentation distinguishes Epitalon free base from Epitalon acetate and notes inconsistencies between some nominated identities and supplied documentation. This is a practical reason to compare a report with the full specification rather than matching the front-label name alone. FDA presentation, identity sections — PDF
Epithalamin is a separate name to watch for. A frequently cited 2003 human longevity report described a clinical assessment involving 266 older people and Thymalin, Epithalamin or combined preparations. The indexed abstract identifies those preparations; it does not identify synthetic Epitalon as the intervention. Its findings must not be relabeled as an Epitalon clinical trial. Original human-study abstract
Name or description | How to interpret it | Check before using it as evidence |
|---|---|---|
Epitalon / Epithalon / AEDG | Alternative reference names | Exact sequence, termini and specified form |
Epitalon acetate | A specified salt form | Whether the report and specification agree |
Epithalamin in the 2003 human report | A differently named study preparation | Do not silently substitute synthetic Epitalon |
“Human cells” | May describe cells maintained in a laboratory | Whether living participants received the intervention |
What did the telomere cell studies find?
The 2003 Khavinson study reported telomerase activity and telomere elongation after exposing human fetal fibroblast cultures to Epithalon. The experiment concerned cells in culture. Its suggestion about possible organism-level effects was an interpretation, not a measured human lifespan result. Original cell-study abstract
In 2025, Al-Dulaimi and colleagues examined normal epithelial and fibroblast cells alongside breast-cancer cell lines. The authors reported telomere-length changes associated with telomerase-related activity in normal cells and alternative lengthening of telomeres, or ALT, in the cancer models. The response depended on the cell model. This was a laboratory study, not a safety or longevity trial in people. Original 2025 report
That distinction matters when a search result compresses the finding into “anti-aging.” A measured cellular endpoint does not tell the reader whether an intervention improves health, how its effects persist, or how benefits and harms balance in a person.
Why the 2025 correction belongs beside the paper
A correction published November 15, 2025 states that incorrect figures had appeared as Figures 1, 2 and 3 and supplies replacements. Readers should use the corrected publication and retain the correction with their notes. This notice is not a retraction, but it is relevant to anyone interpreting or reproducing the displayed results. Publisher's correction
Record the publication version when saving a paper. If a comparison table or illustration was built from an earlier figure, revisit it rather than assuming a citation alone keeps the summary current.
What can the safety evidence establish?
FDA's July 2026 presentation reported that its search had not identified clinical studies assessing Epitalon's safety in humans. It also discussed a small human biomarker study without reported safety data. The presentation explicitly cautioned that a lack of adverse-event reports does not establish safety. These are dated assessment findings, not a complete census of all possible research or a final legal ruling on every use. FDA presentation, clinical-safety sections — PDF
The 2025 cancer-cell findings also should not be turned into either a cancer-treatment claim or proof that Epitalon causes cancer in people. They help identify a biological question; a human-risk conclusion requires different evidence.
A useful checklist for the next Epitalon paper
Copy the exact intervention name and form. Flag any switch between Epitalon and Epithalamin.
Identify the model: isolated cells, an animal experiment or a human intervention.
Separate the measured endpoint from the proposed implication. Telomere length, symptoms and lifespan are different outcomes.
Record the comparator, follow-up and what the report says about adverse-event collection.
Check for corrections and preserve source-access limits in the summary.
Use the study-reading guide for that evidence note. For a supplied research material, the COA checklist addresses the separate task of matching a report to a lot. Published research does not authenticate stock or establish its suitability for human use. Catalog materials are for lawful laboratory research only, not human or veterinary use.
Review method and source access
Checked November 11, 2026: NLM nomenclature, the indexed original abstracts of both 2003 studies, selected publisher text of the 2025 report and its correction, and FDA presentation sections on identity and safety. The check was focused, not systematic; raw datasets and corrected figure measurements were not reanalyzed.
